Kirsten rat sarcoma viral oncogene homologue (KRAS) is one of the most often mutated genes in several cancers such as lung cancer, colorectal cancer, pancreatic cancer, and others.
“Global KRAS Inhibitors Market & Clinical Trials Forecast 2028" Report Highlights:
- KRAS Inhibitors Market Opportunity: > USD 4.5 Billion by 2028
- Initially US To Dominate KRAS Inhibitors Market: >70% Market Share
- Number of KRAS Inhibitors In Trials: > 45 Drugs
- Number of Approved Drugs: 1 (Lumakras)
- Lumakras Dosage, Sales, Patent & Price Insight
- Solid Tumors Targeted Drugs Dominating The Clinical Trials
- Global KRAS Inhibitors Market Trends & Dynamics
- Global KRAS Inhibitors Market Future Opportunity Outlook
Download Report:
https://www.kuickresearch.com/report-global-kras-inhibitors-market-size-sales
Kirsten rat sarcoma viral oncogene homologue (KRAS) is one of the most often mutated genes in several cancers such as lung cancer, colorectal cancer, pancreatic cancer, and others. In last few years, targeting KRAS has emerged out to be attractive strategy owing to the high prevalence of KRAS mutations and its critical role in initiating and sustaining tumor growth. Because of its own characteristics, targeting KRAS was earlier considered impossible. With continuous active exploration, there have been several novel insights to better understand KRAS mutations, promoting the development of drugs targeting KRAS.
Lumakras (sotorasib) is a KRASG12C inhibitor used for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non- small cell lung cancer (NSCLC), following at least one prior systemic therapy. The drug is product of Amgen and was granted FDA approval on 28 May, 2021 based on promising results of overall response rate (ORR) and duration of response (DOR). Apart from US, the drug has been approved in several other countries including Europe, UK, UAE, South Korea, Japan, Canada, and others. In addition to this, Amgen has also submitted marketing authorization applications for review in Australia, Brazil, Saudi Arabia, Taiwan, Turkey, Kuwait, Qatar, Mexico and other regions. The rapid approval of Lumakras globally will drive the growth of market during the forecast period.
Apart from non-small cell lung cancer, researchers are also validating the role of Lumakras in other cancers including colorectal cancer, pancreatic cancer, and other solid tumors which have KRAS G12C mutations. Furthermore, several combinational trials are also ongoing which aim to enhance the efficacy of Lumakaras. The pharmaceutical companies in the global market are actively indulging in collaboration or partnerships to increase the investment in this segment. In 2021, Amgen announced a clinical collaboration with Verestam Oncology to evaluate the combination of VS-6766, Verastem Oncology’s investigational dual RAF/MEK inhibitor with Lumakras in KRAS G12C-mutant non-small cell lung cancer. Further, Boehringer Ingelheim also announced phase-I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1:pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and Lumakras in NSCLC patients.
The promising response of Lumakras in short span of time has also propelled the further research and development activities in this segment. For instance, Adagrasib developed by Mirati Therapeutics is an investigational, highly selective, oral small molecule KRAS inhibitor. In 2021, US FDA has granted breakthrough therapy designation to Adagrasib in patients with non-small cell lung cancer. Further in 2022, US FDA has also accepted new drug application (NDA) for the novel KRAS inhibitor. The prescription drug free user act (PDUFA) date is December 14, 2022. It is suggested that Adagrasib will be available in market by 2023 which will further propel the growth of market during the forecast period.
As per our report findings, the global KRAS inhibitor will surpass US$ 4 Billion by 2028. The high growth rates in the market are mainly attributed to increase in geriatric population and subsequent rise in prevalence of cancer. As per our analysis, forecast period will see rapid influx of KRAS inhibitors in management of wide range of cancers which will further propel the growth of market. In addition, development of favorable reimbursement policies in regions including US and Europe is also propelling the growth in the market. The key players in global KRAS inhibitors market are Merck, Moderna, Revolution Medicines, Eli Lilly, Mirati Therapeutics, Amgen, and others.
The global KRAS inhibitor report involves in depth analysis of the various parameters related to this segment along with the analysis of current as well as future market opportunity. The report also analyzes the wide range of applications of this class in cancer management along with the clinical trends, market drivers, and possible challenges related to KRAS inhibitor market. Further, multiple parameters are considered to forecast and analyze the global, regional and indication based market size for KRAS inhibitors.